ES2623986T3 - Marcadores proteicos para diagnosticar cáncer de estómago y kit de diagnóstico que usa los mismos - Google Patents

Marcadores proteicos para diagnosticar cáncer de estómago y kit de diagnóstico que usa los mismos Download PDF

Info

Publication number
ES2623986T3
ES2623986T3 ES06835536.1T ES06835536T ES2623986T3 ES 2623986 T3 ES2623986 T3 ES 2623986T3 ES 06835536 T ES06835536 T ES 06835536T ES 2623986 T3 ES2623986 T3 ES 2623986T3
Authority
ES
Spain
Prior art keywords
stomach cancer
level
lrg
expression
diagnostic kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06835536.1T
Other languages
English (en)
Inventor
Chul Woo Kim
Syng-Yup Ohn
Mi Young Han
Yong-Sung Shin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioinfra Inc
Original Assignee
Bioinfra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinfra Inc filed Critical Bioinfra Inc
Application granted granted Critical
Publication of ES2623986T3 publication Critical patent/ES2623986T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Abstract

Método de examen in vitro para identificar un grupo de alto riesgo de padecer cáncer de estómago que comprende las siguientes etapas: (1) investigar el nivel de expresión de alfa-2-glicoproteína rica en leucina (LRG) en una muestra obtenida de un paciente; (2) comparar el nivel de expresión de LRG en la muestra con el nivel de expresión de LRG de personas sanas normales; y (3) considerar que el paciente pertenece al grupo de alto riesgo de padecer cáncer de estómago si el nivel de expresión de LRG en la muestra está aumentado en comparación con el nivel de expresión de LRG de personas sanas normales.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
5
10
15
20
25
30
35
5. SC
0,0032 µl
6. NS
0,0064 µl
7. SC
0,0064 µl
8. NS
0,0128 µl
9. SC
0,0128 µl
Alfa-1-antitripsina
1.
Marcador
2.
NS 0,0064 µl
3.
SC 0,0064 µl
4.
NS 0,0096 µl
5.
SC 0,0096 µl
6.
a1 antitripsina 48 ng
[Modo para la invención]
Las realizaciones prácticas y preferidas actualmente de la presente invención son ilustrativas tal como se muestra en los siguientes ejemplos.
Ejemplo 1: Electroforesis en gel bidimensional
<1-1> Obtención de suero
Se obtuvo sangre periférica de pacientes con cáncer de estómago (143 personas) en el Departamento de Cirugía, Facultad de Medicina de la Universidad Nacional de Seúl, durante dos años y medio antes de que los pacientes se sometieran a cirugía y también se obtuvo sangre periférica normal obtenida de personas sanas normales (168 personas) que demostraron no tener cáncer de estómago mediante examen médico en el Green Cross Reference Lab. La sangre se obtuvo usando un tubo Vacutainer SST II (Becton Dickinson) y los sueros se separaron mediante centrifugación.
[Tabla 1] Obtención de suero
imagen8
143 168
estadio
1
2 3 4
cáncer
53 36 34 20 143
Total 311 personas
<1-2> Optimización de las condiciones para electroforesis en gel bidimensional
<1-2-1> Establecimiento de método para electroforesis en gel bidimensional
Se comprobaron diversas condiciones experimentales para mostrar proteoma de suero. En primer lugar, la tira de gradiente de pH (IPG) inmovilizado (Amersham Bioscience) para IEF (isoelectroenfoque) tenía 13 cm de largo y el pH se fijó en el intervalo entre 4 y 7 considerando el tiempo experimental y la detección eficaz del proteoma de suero. Durante el IEF, los voltios-hora totales fueron 62.000 Vh, que se demostró que eran los voltios-hora óptimos. Se determinó que la cantidad de cada muestra para la carga era de 200 ug y la imagen completa generada en la electroforesis en gel bidimensional se muestra en la figura 1-1.
<1-2-2> Establecimiento de un método para el tratamiento de muestras
Para determinar la composición óptima del tampón de rehidratación usado para el análisis del proteoma de suero, se
9
imagen9
imagen10
imagen11

Claims (1)

  1. imagen1
ES06835536.1T 2006-02-28 2006-12-28 Marcadores proteicos para diagnosticar cáncer de estómago y kit de diagnóstico que usa los mismos Active ES2623986T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20060019517 2006-02-28
KR1020060019517A KR100679173B1 (ko) 2006-02-28 2006-02-28 위암 진단용 단백질 마커 및 이를 이용한 진단키트
PCT/KR2006/005836 WO2007100183A1 (en) 2006-02-28 2006-12-28 Protein markers for diagnosing stomach cancer and the diagnostic kit using them

Publications (1)

Publication Number Publication Date
ES2623986T3 true ES2623986T3 (es) 2017-07-12

Family

ID=38105480

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06835536.1T Active ES2623986T3 (es) 2006-02-28 2006-12-28 Marcadores proteicos para diagnosticar cáncer de estómago y kit de diagnóstico que usa los mismos

Country Status (5)

Country Link
US (1) US7892761B2 (es)
EP (1) EP1989552B1 (es)
KR (1) KR100679173B1 (es)
ES (1) ES2623986T3 (es)
WO (1) WO2007100183A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1937815B1 (en) 2005-09-13 2015-05-13 National Research Council of Canada Methods and compositions for modulating tumor cell activity
WO2009091230A2 (ko) * 2008-01-18 2009-07-23 Bioinfra Inc. 유방암 모니터링,진단 및 스크리닝용 단백질 마커 및 이를 이용한 유방암 모니터링,진단 및 스크리닝 방법
KR100967614B1 (ko) 2008-03-14 2010-07-05 주식회사 바이오인프라 Ｄｅｓ－Ｒ 프로트롬빈 활성 펩티드 단편 Ｆ２의 혈청 내농도 측정을 통한 암의 진단 및 스크리닝 방법
CA3013992A1 (en) * 2008-12-30 2010-07-08 Children's Medical Center Corporation Method of predicting acute appendicitis
SG168431A1 (en) * 2009-07-23 2011-02-28 Univ Singapore Cancer biomarker and the use thereof
DK2504363T3 (da) 2009-11-24 2019-07-29 Alethia Biotherapeutics Inc Anti-clusterin-antistoffer og antigenbindende fragmenter og deres anvendelse til reducering af tumorvolumen
WO2011097960A1 (en) * 2010-02-11 2011-08-18 The Hong Kong Polytechnic University Biomarkers of gastric cancer and use thereof
US20120171694A1 (en) * 2010-07-30 2012-07-05 Vermillion, Inc. Predictive markers and biomarker panels for ovarian cancer
ES2656150T3 (es) * 2011-11-14 2018-02-23 Universitätsklinikum Jena Diagnóstico de la sepsis y del síndrome de respuesta inflamatoria sistémica
AU2013210776B2 (en) * 2012-01-20 2018-11-22 Adelaide Research & Innovation Pty Ltd Biomarkers for gastric cancer and uses thereof
MX2014010164A (es) 2012-02-22 2014-11-25 Alethia Biotherapeutics Inc Co-uso de un inhibidor de clusterina con un inhibidor de egfr para tratar cancer.
ES2759026T3 (es) * 2013-02-26 2020-05-07 Inst Oftalmologico Fernandez Vega S L Método para el diagnóstico de glaucoma basándose en la determinación de niveles de proteínas séricas
US20140279752A1 (en) * 2013-03-14 2014-09-18 Opera Solutions, Llc System and Method for Generating Ultimate Reason Codes for Computer Models
KR20150072207A (ko) * 2013-12-19 2015-06-29 한국기초과학지원연구원 대사체학을 이용한 위암 진단 방법
JP7064121B2 (ja) * 2016-05-27 2022-05-10 富士フイルム和光純薬株式会社 消化器癌の判定方法
KR102018209B1 (ko) * 2017-07-24 2019-09-05 (주) 바이오인프라생명과학 위암 진단용 조성물 및 상기 조성물을 이용한 위암 진단 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
EP1394182A1 (en) 2002-07-08 2004-03-03 Europroteome AG Agents and methods for diagnosis and therapy of cancer and cancer risk assessment
WO2005027733A2 (en) * 2003-09-18 2005-03-31 Ppd Biomarker Discovery Sciences, Llc Biological markers for diagnosing multiple sclerosis
WO2005113831A2 (en) * 2004-05-19 2005-12-01 Ppd Biomarker Discovery Sciences, Llc Biomarkers for multiple sclerosis and methods of use thereof
KR100645979B1 (ko) * 2004-08-09 2006-11-15 한국생명공학연구원 위암 유전자 마커 및 이를 이용한 위암 진단킷트

Also Published As

Publication number Publication date
EP1989552A4 (en) 2009-05-06
WO2007100183A1 (en) 2007-09-07
US7892761B2 (en) 2011-02-22
EP1989552A1 (en) 2008-11-12
EP1989552B1 (en) 2017-02-08
US20090018026A1 (en) 2009-01-15
KR100679173B1 (ko) 2007-02-06

Similar Documents

Publication Publication Date Title
ES2623986T3 (es) Marcadores proteicos para diagnosticar cáncer de estómago y kit de diagnóstico que usa los mismos
ES2589530T3 (es) Patrón cuantitativo para espectrometría de masas de proteínas
ES2394925T3 (es) Uso de N-miristoiltransferasa en tejido no tumoral para el diagnóstico de cáncer
Voller Fluorescent antibody methods and their use in malaria research
CN106148524A (zh) 研究人体无精症和严重少精症快速检测的方法及应用其方法的试剂盒
Kumar et al. Assessment of anti-CarP antibodies, disease activity and quality of life in rheumatoid arthritis patients on conventional and biological disease-modifying antirheumatic drugs
ES2531368T3 (es) Métodos y kits para diagnosticar tumorigenicidad y determinar resistencia a los efectos antineoplásicos de la terapia antiestrógeno
CN109142565A (zh) 基于iTRAQ技术的胎膜早破孕妇阴道分泌物差异蛋白的筛选方法
CN103981288A (zh) 一种非诊疗目的禽肿瘤性病毒多重pcr检测方法
Gordon Smith et al. Immunofluorescent reactions with microfilariae: 1. Diagnostic evaluation
CN106075468A (zh) Gps2用于制备软组织肿瘤预后、诊断或防治的药物的用途
JP2019144218A (ja) バイオマーカー
ES2733002T3 (es) Método para la detección mejorada de células inmunitarias específicas de antígeno que infiltran el tejido
Kabanova et al. Systemic inflammatory response syndrome and serum Procalcitonin in odontogenic maxillofacial infection
CN112147336B (zh) 一种检测和评估肝再生的标志物及其用途
Meents et al. Schistosoma haematobium prevalence in school children in the rural Eastern Cape Province, South Africa
Shirazi et al. Isolation and purification of Echinococcus granulosus antigen B from hydatid cyst fluid using three different methods
Reiner et al. Prevalence of TBE antibodies in serum and CSF of dogs with inflammatory and non-flammatory CNS disease
Darabian et al. Association between Blastocystis hominis and irritable bowel syndrome (IBS)
Shields et al. Differential Adipose Tissue Proteomics
CN104777300A (zh) 一种白塞氏病检测的生物标志物及其用途
TWI429908B (zh) 腦外傷神經傷害之體外檢測方法
Prasetya et al. Polyclonal antibody from 47ákDa protein of bladder cancer is sensitive and specific for detection of bladder cancer
Santarém et al. Diagnosis of visceral leishmaniasis
ES2381950B2 (es) Liposomas con anticuerpos contra marcadores de la zona peri-infarto cerebral.